Oncternal Therapeutics Inc (ONCT)
US Market

Oncternal Therapeutics (ONCT) Financial Statements


Oncternal Therapeutics Financial Overview

Oncternal Therapeutics's market cap is currently ―. The company's EPS TTM is $-12.342; its P/E ratio is -0.76; Oncternal Therapeutics is scheduled to report earnings on August 8, 2024, and the estimated EPS forecast is $-2.58. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue$ 179.00K$ 106.00K$ 203.00K$ 171.00K$ 0.00
Gross Profit$ 179.00K$ 106.00K$ 203.00K$ 171.00K-
EBIT$ -9.86M$ -8.97M$ -11.49M$ -11.86M$ -11.32M
EBITDA$ -9.86M$ -9.43M$ -11.93M$ -11.93M$ -11.32M
Net Income Common Stockholders$ -9.86M$ -8.97M$ -11.49M$ -11.34M$ -11.13M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 40.30M$ 45.50M$ 54.32M$ 63.72M$ 70.63M
Total Assets$ 43.20M$ 50.77M$ 58.28M$ 68.65M$ 76.17M
Total Debt$ 342.00K$ 366.00K$ 50.00K$ 87.00K$ 122.00K
Net Debt$ -39.96M$ -45.14M$ -54.27M$ -63.64M$ -70.51M
Total Liabilities$ 6.20M$ 5.59M$ 5.79M$ 68.65M$ 7.63M
Stockholders Equity$ 37.00M$ 45.14M$ 52.48M$ 60.97M$ 68.54M
Cash Flow-
Free Cash Flow$ -5.51M$ -9.26M$ -10.97M$ -9.00M$ -11.97M
Operating Cash Flow$ -5.51M$ -9.26M$ -10.97M$ -9.00M$ -11.97M
Investing Cash Flow$ 4.66M$ 13.85M$ -16.05M$ -26.50M-
Financing Cash Flow$ -49.00K$ -1.00K$ 1.12M$ 2.01M$ 3.69M
Currency in USD

Oncternal Therapeutics Earnings and Revenue History

Oncternal Therapeutics Debt to Assets

Oncternal Therapeutics Cash Flow

Oncternal Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis